Investigation of Efficacy and Safety of Botulinum Toxin A (Botox-Allergan Inc) in Migraine Headaches

Refractory Migraine Clinical Trial

Official title:
Investigation of Efficacy and Safety of Botulinum Toxin A (Botox-Allergan Inc) in Migraine Headaches

Status Completed

Clinical Trial Summary

The hypothesis of this study is that injection of botulinum toxin A into the muscles around the head (frontal, temporal, posterior neck, occipital) can reduce the intensity and frequency of migraine headaches by 50%.

Clinical Trial Description

Contact PI for study details ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00660192
Study type	Interventional
Source	Yale University
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	January 2008
Completion date	July 2015

View Details

See also
	Status	Clinical Trial	Phase
	Not yet recruiting	`NCT06462781` - Localized Injection of Lidocaine and Glucocorticoid for Headache Treatment	Phase 2
	Completed	`NCT01670214` - Pulsed Electromagnetic Field Therapy in the Refractory Migraine	N/A